[加泰罗尼亚胃肠病学会立场文件：三联疗法治疗1型慢性丙型肝炎病毒] - Suppr

Suppr

超能文献

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].

作者信息

Bruguera Miquel, Esteban Rafael, Forns Xavier, Planas Ramón, Quer Juan Carlos, Solà Ricard, Vergara Mercè

机构信息

Hospital Clínic, Barcelona, España.

出版信息

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3.

DOI:10.1016/j.gastrohep.2012.03.005

PMID:22560187

Abstract

摘要

相似文献

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934.

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:19-25. doi: 10.1016/S0213-005X(13)70120-4.

[Conclusions].

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:49-50. doi: 10.1016/S0213-005X(13)70124-1.

Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.

PLoS One. 2017 Jan 24;12(1):e0170667. doi: 10.1371/journal.pone.0170667. eCollection 2017.

Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.

Aliment Pharmacol Ther. 2014 Jun;39(11):1342-4. doi: 10.1111/apt.12748.

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

Lancet Infect Dis. 2012 Sep;12(9):717-28. doi: 10.1016/S1473-3099(12)70060-9. Epub 2012 May 29.

[Therapy of chronic Hepatitis C in 2008].

MMW Fortschr Med. 2008 Mar 27;150(13):31-4. doi: 10.1007/BF03365407.

Telaprevir for the treatment of chronic hepatitis C infection.

Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14. doi: 10.1586/eri.11.133.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

引用本文的文献

Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.

PLoS One. 2013 Aug 28;8(8):e72600. doi: 10.1371/journal.pone.0072600. eCollection 2013.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].

作者信息

Bruguera Miquel, Esteban Rafael, Forns Xavier, Planas Ramón, Quer Juan Carlos, Solà Ricard, Vergara Mercè

机构信息

Hospital Clínic, Barcelona, España.

出版信息

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3.

DOI:10.1016/j.gastrohep.2012.03.005

PMID:22560187

Abstract

摘要

相似文献

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934.

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:19-25. doi: 10.1016/S0213-005X(13)70120-4.

[Conclusions].

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:49-50. doi: 10.1016/S0213-005X(13)70124-1.

Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.

PLoS One. 2017 Jan 24;12(1):e0170667. doi: 10.1371/journal.pone.0170667. eCollection 2017.

Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.

Aliment Pharmacol Ther. 2014 Jun;39(11):1342-4. doi: 10.1111/apt.12748.

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

Lancet Infect Dis. 2012 Sep;12(9):717-28. doi: 10.1016/S1473-3099(12)70060-9. Epub 2012 May 29.

[Therapy of chronic Hepatitis C in 2008].

MMW Fortschr Med. 2008 Mar 27;150(13):31-4. doi: 10.1007/BF03365407.

Telaprevir for the treatment of chronic hepatitis C infection.

Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14. doi: 10.1586/eri.11.133.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

引用本文的文献

Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.

PLoS One. 2013 Aug 28;8(8):e72600. doi: 10.1371/journal.pone.0072600. eCollection 2013.